{"id":1013807,"date":"2026-10-27T02:03:02","date_gmt":"2026-10-27T06:03:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/"},"modified":"2026-10-27T02:03:02","modified_gmt":"2026-10-27T06:03:02","slug":"innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/","title":{"rendered":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC<\/i><\/b><\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study.<\/p>\n<p>\nPACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemoradiation therapy. Enrollment in the trial is complete.<\/p>\n<p>\nMonalizumab is an anti-NKG2A antibody developed by Innate Pharma in collaboration with AstraZeneca. AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialisation agreement initiated in 2015.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n<p>\nHeadquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54628744&amp;newsitemid=20261026687365&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=1&amp;md5=6588c62b5a19e1a298820efab0139588\">www.innate-pharma.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54628744&amp;newsitemid=20261026687365&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=126421d2a299384aa7ff5f4a4336d1cd\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54628744&amp;newsitemid=20261026687365&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=8ed96ba68f506a75bf67f4529f3523d0\">X<\/a>.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<p>\nISIN code: FR0010331421<br \/>\n<br \/>Ticker code: Euronext Paris: IPH | Nasdaq: IPHA<br \/>\n<br \/>LEI: 9695002Y8420ZB8HJE29<\/p>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54628744&amp;newsitemid=20261026687365&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=4&amp;md5=cc750090ff5396d89e5e0b60a87acfd2\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261026687365\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261026687365\/en\/<\/a><\/span><\/p>\n<p>\nSt\u00e9phanie Cornen<br \/>\n<br \/>VP, Investor Relations &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.cornen@innate-pharma.fr\">stephanie.cornen@innate-pharma.fr<\/a><\/p>\n<p>\nInvestor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@innate-pharma.fr\">investors@innate-pharma.fr<\/a><\/p>\n<p>\nMedia<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communication@innate-pharma.fr\">communication@innate-pharma.fr<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Maryland Europe United States North America France<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261026687365\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed &hellip; Continue reading &quot;Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T06:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027\",\"datePublished\":\"2026-10-27T06:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/\"},\"wordCount\":595,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/\",\"name\":\"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-27T06:03:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk","og_description":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed &hellip; Continue reading \"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T06:03:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027","datePublished":"2026-10-27T06:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/"},"wordCount":595,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/","name":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-27T06:03:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261026687365r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}